#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myelofibrosis Cutaneous T-cell lymphoma refractory Adenomatous polyposis coli Vernal keratoconjunctivitis Demyelination Acute graft versus host disease in skin Endometrial cancer recurrent Salivary gland cancer Erythema multiforme Haemophilia Cystic fibrosis lung Soft tissue sarcoma Pulmonary arterial hypertension Congenital pseudarthrosis Aplastic anaemia More trials…

    Learn about Rare Diseases

    Cerebral arteriovenous malformation haemorrhagic – Trials in Disease Osteosarcoma recurrent Hereditary angioedema – Basic Information Mucopolysaccharidosis II Hepatoblastoma Angiosarcoma metastatic – Diagnostics Myxofibrosarcoma – Treatment Pleomorphic leiomyosarcoma – Basic Information Congenital generalised lipodystrophy – Diagnostics Atypical haemolytic uraemic syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Human Plasma Protein Ertapenem Verapamil Rezpegaldesleukin ANXV Methoxyflurane Botaretigene Sparoparvovec Iclepertin Mepacrine Clopidogrel Triamcinolone Acetonide Ethanol, Anhydrous Diphenhydramine Fulvestrant Perampanel Vh4524184 Belzupacap Sarotalocan AP31969 SULFATE Adapalene Quercus Robur Pollen Extract More therapies…

    Learn about Your Condition

    Short-bowel syndrome Erosive oesophagitis Neuralgia Non-Hodgkin's lymphoma Thermal burn Hepatic adenoma Cold urticaria Coronary artery dissection Procedural haemorrhage Nephropathy Weaning failure Fabry's disease T-cell lymphoma Sickle cell disease Thymoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Systemic lupus erythematosus

  • Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

    Recruiting

    3 1 1
    Investigated Drugs:
    • Anhydrous Caffeine
    • Camphor
    • Dapirolizumab Pegol
    Belgium Denmark France Germany Greece Italy +3

  • Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Anhydrous Caffeine
    • Camphor
    • Dapirolizumab Pegol
    Belgium Bulgaria Czechia Denmark France Germany +7

  • Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Anifrolumab
    France Germany Italy Poland Spain

  • BI 3000202 in Patients with Moderate to Severe Systemic Lupus Erythematosus

    Recruiting

    2 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Bulgaria Croatia Germany Hungary Poland Romania +1

  • Obinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Obinutuzumab
    France

  • A Study of Obecabtagene Autoleucel for Patients with Severe Lupus and Active Kidney Inflammation Not Responding to Standard Treatment

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Lupus nephritis
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Autologous Enriched T Cells Retrovirally Transduced To Express Two Chimeric Antigen Receptors Targeting Cd19 And Cd22
    • Fludarabine Phosphate
    • Cyclophosphamide
    Greece
Previous Page
1 2 3 4 5 6 … 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!